Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $12,482.54 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,829 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $3.26, for a total value of $12,482.54. Following the transaction, the chief technology officer now directly owns 1,749,541 shares of the company’s stock, valued at $5,703,503.66. This represents a 0.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Stock Down 2.1 %

Shares of Sight Sciences stock opened at $3.25 on Friday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a twelve month low of $3.16 and a twelve month high of $8.45. The company has a market cap of $164.95 million, a price-to-earnings ratio of -3.19 and a beta of 2.57. The company’s 50 day moving average is $3.82 and its 200 day moving average is $5.52.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $20.41 million. Research analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Sight Sciences

Institutional investors have recently made changes to their positions in the business. Barclays PLC increased its holdings in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after buying an additional 38,248 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares during the period. Millrace Asset Group Inc. purchased a new stake in shares of Sight Sciences in the 3rd quarter worth $874,000. State Street Corp increased its stake in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in Sight Sciences by 256.6% during the second quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock valued at $556,000 after purchasing an additional 60,220 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

SGHT has been the topic of several recent research reports. Piper Sandler restated a “neutral” rating and issued a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Lake Street Capital downgraded Sight Sciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $10.00 to $5.00 in a report on Monday, November 4th. UBS Group assumed coverage on shares of Sight Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $5.50 price target on the stock. Citigroup reduced their price objective on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Finally, Morgan Stanley cut their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $5.12.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.